By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

A US mum says a new Wegovy weight-loss pill has helped restart her progress after injections proved too expensive. Sharon Vickers, 46, paid $149 a month for the tablets after her weight loss stalled ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

The appetite-suppressing diet which is ‘like Mounjaro but with food’ - The ‘zone diet’ was created in 1995 and designed to ...

The maker of Ozempic is facing stiff competition from rival obesity drug companies, as well as unproven knock-offs from China ...

While CagriSema bested Novo Nordisk's Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma's 25% weight loss goal.

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

A mom who couldn’t afford GLP-1 injections has started the new “cheaper” Wegovy pill – and says she has no side effects. Sharon Vickers, 46, has struggled with her weight all her life and at her ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday, a new ...

Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its ...